This is an old revision of this page, as edited by Boghog (talk | contribs) at 06:19, 24 December 2024 (consistent citation formatting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:19, 24 December 2024 by Boghog (talk | contribs) (consistent citation formatting)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Pharmaceutical compound
 | |
| Clinical data | |
|---|---|
| Trade names | 高瑞哲 |
| Other names | AZD-4205, AZD4205, JAK1-IN-3 |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H31N9O2 |
| Molar mass | 489.584 g·mol |
Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Golidocitinib is classified as a Janus kinase inhibitor.
References
- Keam SJ (October 2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
- Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. (January 2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
- Jin J, Zhang L, Zou L, Li Z, Wu H, Zhou K, et al. (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |